

HR 7269

Promising Pathway Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Jun 18, 2020

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Jun 18, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/7269>

Sponsor

Name: Rep. Quigley, Mike [D-IL-5]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors (11 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Gallagher, Mike [R-WI-8]	R · WI		Jun 18, 2020
Rep. Swalwell, Eric [D-CA-15]	D · CA		Jun 18, 2020
Rep. Westerman, Bruce [R-AR-4]	R · AR		Jun 18, 2020
Rep. Napolitano, Grace F. [D-CA-32]	D · CA		Jul 16, 2020
Rep. Van Drew, Jefferson [R-NJ-2]	R · NJ		Jul 16, 2020
Rep. Bacon, Don [R-NE-2]	R · NE		Jul 23, 2020
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		Jul 24, 2020
Rep. Craig, Angie [D-MN-2]	D · MN		Jul 29, 2020
Rep. King, Peter T. [R-NY-2]	R · NY		Jul 29, 2020
Rep. Beatty, Joyce [D-OH-3]	D · OH		Aug 14, 2020
Rep. Yoho, Ted S. [R-FL-3]	R · FL		Aug 21, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Jun 18, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 3872	Identical bill	Jun 3, 2020: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Promising Pathway Act

This bill establishes a provisional approval pathway for medicines intended for serious or life-threatening diseases, including illnesses posing a threat of epidemic or pandemic. The period of the provisional approval is for two years and is potentially renewable.

The Food and Drug Administration (FDA) must establish a priority review system to evaluate completed provisional approval applications within 90 days of receipt. A provisional approval application may be approved if the FDA determines that (1) there is substantial evidence of safety for the drug; and (2) there is relevant early evidence of efficacy, based on adequate and well-controlled investigations.

During the COVID-19 (i.e., coronavirus disease 2019) pandemic, or another epidemic or pandemic, the FDA must accept and review various portions of a provisional approval application on a rolling basis.

The manufacturer of a provisionally approved drug must require patients to participate in an observational registry. A manufacturer that fails to comply with registry requirements is subject to civil penalties.

A provisionally approved drug must be labeled as such.

If a drug that receives provisional approval status is not brought to market within 180 days of the approval, the approval must be rescinded.

The bill also limits the liability of a manufacturer of a provisionally approved drug with respect to any claim under state law alleging that the drug is unsafe or ineffective.

Private health insurers and federal health care programs shall not deny coverage of a provisionally approved drug on the basis of it being experimental.

Actions Timeline

- **Jun 18, 2020:** Introduced in House
- **Jun 18, 2020:** Referred to the House Committee on Energy and Commerce.

LegiList

CONGRESS, MADE CLEAR.

Search Every Federal Bill, Law, and Vote

LegiList is the fastest way to research Congress. Track any bill from introduction to enactment, see how every legislator voted, follow committee activity, and read the full text of every bill — all in one place, always up to date.

legilist.com

Free Course: Learn How Congress Actually Works

LegiList Learn is a free, self-paced course that walks through the entire legislative process — from drafting a bill to a presidential signature. Seven modules, plain language, no politics. Earn a certificate when you finish.

legilist.com/learn

Developer API: Build Apps on Legislative Data

The LegiList API gives developers direct access to bills, votes, legislators, committees, and more. Start free with 1,000 requests per day — no credit card required. Upgrade to Pro when you need to scale.

legilist.com/api

Public data belongs to the public. — legilist.com